MacroChem CEO to Present March 16 in Boston at Sachs-Bloomberg Forum: Investing & Partnering in Biotech & Medtech LEXINGTON, Mass., March 15 /PRNewswire-FirstCall/ -- MacroChem Corporation (NasdaqSC: MCHM), a specialty pharmaceutical company, announced today that Robert J. DeLuccia, president and chief executive officer, will speak on the company and its products in clinical development at the Sachs-Bloomberg 4th Annual North American Forum: Investing & Partnering in Biotech & Medtech. Mr. DeLuccia's presentation, on Wednesday, March 16, 2005 at 10:55 AM, will be webcast on http://www.sachsforum.com/, the Sachs-Bloomberg Forum web site. Following the Forum, it will also be available at http://www.macrochem.com/, the MacroChem web site. The Sachs-Bloomberg Forum will be held at the Fairmont Copley Plaza Hotel in Boston, March 16-17. Professional investors and corporate attendees will hear presentations from private and publicly funded biotechnology and medical technology companies, and venture capitalists specializing in these fields. In his presentation, Mr. DeLuccia will review the MacroChem business strategy -- the development and commercialization of innovative products that capitalize on the company's proprietary drug delivery technology, SEPA(R). He will also discuss MacroChem's two SEPA-enhanced products currently in clinical development: Opterone(R), a topical testosterone/SEPA cream for treating male hypogonadism, and EcoNail(TM), an econazole/SEPA nail lacquer for treating onychomycosis (fungal infection of the nails). Opterone is currently in a bioavailability study, with results expected later this year. In 2004, MacroChem completed an EcoNail Phase 1 safety- tolerability study in onychomycosis patients, and expects to advance to an efficacy trial in 2005. For four years, the Sachs-Bloomberg Forum has been a leading international forum for companies interested in investing and partnering in the biotechnology and medical technology industries. It typically attracts more than 450 attendees. The event features executive roundtables, presentations by mid-caps, small-caps, IPO prospects and venture-backed companies. About MacroChem MacroChem is a specialty pharmaceutical company that innovates, develops and commercializes pharmaceuticals administered in novel ways, to treat important medical conditions. MacroChem is developing two products containing its patented enhancer, SEPA(R): Opterone(R), a SEPA-enhanced topical testosterone treatment for male hypogonadism; and EcoNail(TM), a SEPA-enhanced antifungal nail lacquer to treat a common and potentially debilitating nail infection known as onychomycosis. For more information on MacroChem, and its technology and products, please visit our website at: http://www.macrochem.com/. Forward-Looking Statements With the exception of historical information contained in this press release, the matters described herein are forward-looking statements that involve risks and uncertainties. MacroChem's actual results may differ significantly from the results discussed in the forward-looking statements. Factors that might cause such a difference include, but are not limited to, those discussed or referred to in the section entitled "Risk Factors" in MacroChem's Annual Report on Form 10-K, as well as those discussed elsewhere therein, and include, without limitation, risks regarding product development, the timing and results of clinical trials, the regulatory approval process, capital requirements, financial condition, patent protection and dependence on third parties for development and licensing arrangements. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. MacroChem undertakes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise. For more information on Sachs-Bloomberg please visit their website, http://www.sachsforum.com/ DATASOURCE: MacroChem Corporation CONTACT: Investor Contact: Bernard Patriacca, VP/CFO of MacroChem Corporation, +1-781-862-4003; or Media Contact: Donna LaVoie of LaVoie Group, +1-781-596-0200 ext. 103 Web site: http://www.macrochem.com/

Copyright